Baseline demographic and disease characteristics.
| Characteristics | IV Placebo | IV Golimumab, 2 mg/kg |
|---|---|---|
| Patients randomized, n | 239 | 241 |
| Age, yrs | 46.7 ± 12.5 | 45.7 ± 11.3 |
| Male | 121 (50.6) | 128 (53.1) |
| Duration of PsA, yrs | 5.3 ± 5.9 | 6.2 ± 6.0 |
| Swollen joint count (0–66) | 14.1 ± 8.2 | 14.0 ± 8.4 |
| Tender joint count (0–68) | 26.1 ± 14.4 | 25.1 ± 13.8 |
| CRP, mg/dl | 2.0 ± 2.1 | 1.9 ± 2.5 |
| PsA-modified SvdH | 237 (99.2) | 237 (98.3) |
| Total (0–528) | 34.5 ± 53.5 | 35.5 ± 55.2 |
| Erosion (0–320) | 21.1 ± 30.2 | 22.2 ± 31.7 |
| JSN (0–208) | 13.3 ± 24.3 | 13.2± 24.8 |
| Concomitant MTX | 173 (72.4) | 163 (67.6) |
| Dose, mg/week | 14.9 ± 4.8 | 14.8 ± 4.7 |
| Concomitant NSAID | 165 (69.0) | 169 (70.1) |
| Concomitant oral corticosteroids | 66 (27.6) | 65 (27.0) |
Data are presented as n (%) or mean ± SD. CRP: C-reactive protein; IV: intravenous; JSN: joint space narrowing; MTX: methotrexate; PsA: psoriatic arthritis; NSAID: nonsteroidal antiinflammatory drugs; SvdH: Sharp/van der Heijde score.